Production (Stage)
Nexien BioPharma, Inc.
NXEN
$0.0145
$0.00552.63%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -24.75% | -43.09% | -59.56% | -44.94% | -45.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.75% | -43.09% | -59.56% | -44.94% | -45.40% |
| Operating Income | 24.75% | 43.09% | 59.56% | 44.94% | 45.40% |
| Income Before Tax | 23.60% | 22.61% | 42.63% | 33.95% | 32.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.60% | 22.61% | 42.63% | 33.95% | 32.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.60% | 22.61% | 42.63% | 33.95% | 32.62% |
| EBIT | 24.75% | 43.09% | 59.56% | 44.94% | 45.40% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 28.21% | 27.27% | 45.45% | 37.29% | 35.00% |
| Normalized Basic EPS | 26.09% | 26.92% | 45.45% | 38.89% | 37.84% |
| EPS Diluted | 28.21% | 27.27% | 45.45% | 37.29% | 35.00% |
| Normalized Diluted EPS | 26.09% | 26.92% | 45.45% | 38.89% | 37.84% |
| Average Basic Shares Outstanding | 8.06% | 7.92% | 7.05% | 6.19% | 5.59% |
| Average Diluted Shares Outstanding | 8.06% | 7.92% | 7.05% | 6.19% | 5.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |